What Is MGM-15 (Dihydro-7-Hydroxymitragynine)? Evidence, Pharmacology, and Risks

What Is MGM-15 (Dihydro-7-Hydroxymitragynine)? Evidence, Pharmacology, and Risks

Strong safety notice: This page is for research literacy and harm-reduction context only. MGM-15 is an opioid-acting semi-synthetic compound with no established safe human dose and no FDA-approved medical use. If exposure has already occurred and there are symptoms such as slowed breathing, unconsciousness, blue lips, severe sedation, chest pain, or inability to stay awake, seek emergency medical help immediately.

Quick answer

MGM-15 is another name used for dihydro-7-hydroxymitragynine, a semi-synthetic derivative related to 7-hydroxymitragynine (7-OH). It is not the same thing as traditional kratom leaf, and it should not be treated as a clinically characterized medicine or ordinary dietary supplement.

The evidence base is dominated by medicinal chemistry, preclinical pharmacology, forensic identification, and public-health monitoring. Controlled human pharmacokinetic, dose-ranging, safety, efficacy, dependence, and overdose studies have not established a safe or medically accepted use.

Evidence grade for human effects: Very Low.

What is MGM-15?

MGM-15 is a market and research name used for dihydro-7-hydroxymitragynine, also described as a 1,2-dihydro derivative of 7-hydroxymitragynine. It belongs to the broader family of compounds derived from or inspired by kratom alkaloid chemistry, but it is better understood as a semi-synthetic opioid-acting derivative than as a normal constituent of traditional kratom leaf.

That distinction matters. Whole-leaf kratom contains a complex alkaloid mixture dominated by mitragynine. MGM-15 is a chemically modified derivative encountered in a very different product and exposure context.

Forensic monitoring groups including the Center for Forensic Science Research and Education (CFSRE) have published a monograph and public alert for dihydro-7-hydroxymitragynine/MGM-15, documenting its appearance in the novel-psychoactive-substance market.

Is MGM-15 naturally found in kratom?

Not as a normal constituent of traditional kratom leaf products. MGM-15 is described as a semi-synthetic derivative related to 7-hydroxymitragynine.

That means evidence about ordinary kratom leaf cannot simply be transferred to MGM-15. Differences in chemical identity, concentration, formulation, route of exposure, and product composition can substantially change risk.

Names and chemical identity

Analytical reports also note practical testing challenges. CFSRE has described conversion artifacts during some analytical workflows, which can complicate identification and quantification if methods are not validated for MGM-15 specifically.

Pharmacology: what is actually known?

Available pharmacology is primarily preclinical. Medicinal-chemistry work on 7-hydroxymitragynine-derived analogues demonstrates substantial opioid-receptor activity, including mu-opioid and delta-opioid receptor signaling in laboratory systems.

The most important limitation is that receptor affinity or activity in a laboratory assay is not a clinically meaningful human potency ranking by itself. Results can change with assay design, receptor system, measured endpoint, species, exposure level, metabolism, and formulation.

Is MGM-15 stronger than 7-OH?

There is not enough human evidence to give a reliable clinical answer. Some laboratory work on related compounds reports high opioid-receptor activity, but cross-compound rankings depend on the exact assay and endpoint being compared.

A statement such as “MGM-15 is X times stronger than 7-OH” can therefore be misleading when it is detached from the specific receptor assay, concentration range, animal model, or formulation that produced the number.

For a side-by-side evidence review, see 7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl. The comparison page intentionally avoids turning preclinical receptor measurements into a universal human potency ranking.

Does MGM-15 have human studies?

No controlled human clinical trials have established MGM-15 safety, pharmacokinetics, efficacy, dependence liability, or an accepted medical dose range.

That absence of data is especially important for an opioid-acting compound. It leaves major questions unresolved:

• how quickly the compound is absorbed and cleared in people;
• whether active metabolites materially contribute to effects;
• how respiratory-depression risk changes with dose;
• how rapidly tolerance or physical dependence can develop;
• whether withdrawal differs from other opioid-active kratom derivatives;
• how alcohol, benzodiazepines, gabapentinoids, opioids, sleep medications, or other depressants alter risk;
• how often commercial products are mislabeled or contain additional active ingredients.

The lack of a controlled human evidence base should not be interpreted as evidence of safety.

Safety and risk

MGM-15 should be treated as a high-risk, poorly characterized opioid derivative. Major concerns include respiratory depression, profound sedation, impaired driving, physical dependence, withdrawal, overdose, accidental pediatric exposure, and unpredictable interactions with other central nervous system depressants.

Unregulated products add another layer of uncertainty:

• Label claims may not match actual contents.
• Tablets, powders, and liquids may vary in concentration.
• Products may contain other kratom derivatives, synthetic opioids, sedatives, or contaminants.
• Consumers may mistake semi-synthetic opioid products for traditional kratom leaf.
• Analytical identification can be difficult without appropriate reference standards and validated methods.

Harm-reduction warning: If someone has already taken an opioid-acting product and develops severe sedation, slowed or abnormal breathing, confusion, collapse, blue lips, or loss of consciousness, treat it as a medical emergency. Naloxone may be relevant when opioid toxicity is suspected, but it is not a substitute for emergency care.

MGM-15 vs traditional kratom leaf

MGM-15 vs 7-OH vs mitragynine pseudoindoxyl

These compounds are related to the kratom alkaloid pathway but should not be collapsed into one exposure category.

• 7-Hydroxymitragynine (7-OH) has a larger preclinical and emerging human-safety literature than MGM-15.
• MGM-15 has very limited human evidence and is best treated as an emerging semi-synthetic opioid derivative.
• Mitragynine pseudoindoxyl is a distinct compound with its own pharmacology, metabolism, product-market context, and emerging withdrawal reports.

Because laboratory assays are not interchangeable, this site does not present a single assay-independent “strongest to weakest” ranking as though it were a validated human potency scale.

Frequently asked questions

Is MGM-15 the same as “7-OH”?

No. MGM-15 is related to 7-hydroxymitragynine but is a distinct dihydro derivative. Product labels that use these names interchangeably should be treated cautiously.

Is MGM-15 a supplement?

Calling it a supplement can obscure the evidence. MGM-15 is a semi-synthetic opioid-acting derivative with no established safe human dose and no FDA-approved medical use.

Is there a safe MGM-15 dose?

No controlled human evidence establishes a safe or medically accepted dose range. Online dose charts or anecdotal thresholds should not be treated as clinical evidence.

Can MGM-15 cause dependence or withdrawal?

Its opioid-receptor pharmacology makes dependence and withdrawal biologically plausible, but MGM-15-specific human incidence, time course, and severity are not well characterized. Evidence from related compounds cannot supply those missing MGM-15-specific data.

Why is MGM-15 showing up in forensic alerts?

Forensic monitoring organizations have identified dihydro-7-hydroxymitragynine/MGM-15 in the emerging drug market. That surveillance is important because commercial availability can expand before controlled human research catches up.

Related evidence

• Substance Use, Dependence & Harm Reduction hub
• 7-Hydroxymitragynine evidence review
• Mitragynine evidence review
• Mitragynine pseudoindoxyl
• 7-OH vs MGM-15 vs Mitragynine Pseudoindoxyl
• Kratom & 7-OH withdrawal: evidence and clinical context
• Kratom-derived semi-synthetic opioids
• Novel psychoactive substances

Key takeaways

• MGM-15 is another name used for dihydro-7-hydroxymitragynine.
• It is a semi-synthetic derivative related to 7-OH, not traditional kratom leaf.
• Preclinical evidence supports opioid-receptor activity, but controlled human safety and pharmacokinetic data are lacking.
• Laboratory potency numbers should not be converted into a universal human potency ranking.
• Product identity, concentration, co-ingredients, dependence risk, withdrawal severity, and overdose risk remain poorly characterized.

Search methodology

This article prioritizes peer-reviewed medicinal chemistry and pharmacology papers, forensic monographs and alerts, public-health sources, and regulatory information. Human claims are separated from preclinical findings, and cross-compound potency claims are treated as assay-specific unless supported by controlled human evidence.